- Delivering Pan India
Berirab P® (Human Rabies Immunoglobulin) Human rabies immunoglobulin 300 IU/2 mL prefilled syringe by CSL Behring. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Human rabies immunoglobulin 300 IU/2 mL |
|---|---|
| Manufacturer | CSL Behring |
| Country | Germany |
| Pack size | Human rabies immunoglobulin 300 IU/2 mL: 1 prefilled syringe / carton |
| Storage | Store as per carton and leaflet; original sealed pack |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Berirab P® (Human Rabies Immunoglobulin) Human rabies immunoglobulin 300 IU/2 mL Prefilled Syringe — Human Rabies Immune Globulin: A Sourcing Guide for Hospitals and Pharmacies
Berirab® P is a brand of human rabies immunoglobulin (300 IU in a 2 mL prefilled syringe), manufactured by CSL Behring GmbH, Marburg, Germany. According to the US prescribing information for human rabies immune globulin (HyperRAB®), such products are indicated, together with rabies vaccine, for postexposure prophylaxis in persons with suspected rabies exposure. Use of Berirab P in India is defined by its approved pack insert and the Indian regulator. The decision to prescribe human rabies immunoglobulin, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Berirab P® (human rabies immunoglobulin) Human rabies immunoglobulin 300 IU/2 mL prefilled syringe to hospitals and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the anti-biotic medicines category. Supply is in bulk/wholesale quantities only.
Berirab P contains human rabies immunoglobulin 300 IU in 2 mL (150 IU/mL) as a ready-to-use solution in a prefilled syringe, for infiltration and intramuscular use as described in its pack insert.
How it works, according to the label: The reference label describes rabies immune globulin as providing passive rabies virus neutralising antibodies until the person responds to the vaccine.
The current US prescribing information for HYPERRAB® (rabies immune globulin, human), a reference brand of the same class (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Berirab P pack insert.
The reference label summarises studies of rabies immune globulin with vaccine. The WHO describes rabies as a vaccine-preventable disease and sets out postexposure prophylaxis recommendations in its fact sheet. Evidence is cited for information only and is not a recommendation for any patient; the approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Human rabies immunoglobulin 300 IU/2 mL | Solution for injection, prefilled syringe | 1 prefilled syringe / carton |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, emergency and anti-rabies clinic buyers, and pharmacies that source biologic products. Rabies immune globulin is administered by a physician, as described in the prescribing information.
The HyperRAB label lists, as most common adverse reactions (over 5%), injection-site pain, headache, injection-site nodule, abdominal pain, diarrhea, flatulence, nasal congestion and oropharyngeal pain. It also describes hypersensitivity reactions. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Berirab P carton and leaflet. For reference, the US HyperRAB label describes refrigeration at 2°C to 8°C and states not to freeze. Keep out of reach of children.
Berirab P is marketed by CSL Behring. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Berirab P through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Berirab P available in India?
A.K. Pharma supplies Berirab P (human rabies immunoglobulin) Human rabies immunoglobulin 300 IU/2 mL prefilled syringe to hospitals and pharmacies in India. Contact us for current availability.
What does Berirab P contain?
Human rabies immunoglobulin 300 IU/2 mL in a prefilled syringe, used with rabies vaccine as the label describes.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Berirab P be stored?
Follow the carton; the US reference label describes 2°C to 8°C, not frozen.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
